Market-Moving News for September 16th
Market-Moving News for September 16th
NCNA: 282% | NuCana Presented Final Data From Phase 2 Nutide:701 Study At ESMO Congress On NUC-7738 In Combination With Pembrolizumab For Patients With Metastatic Melanoma Who Were Refractory To Or Had Relapsed On Prior PD-1 Inhibitor Therapy
NCNA：282% | NuCana 在 ESMO 大會上公佈了 2 期 Nutide: 701 研究的最終數據，該研究涉及 NUC-7738 與 Pembrolizumab 聯合用於先前 PD-1 抑制劑療法難治或復發的轉移性黑色素瘤患者
ZNTL: 49% | Zentalis Pharmaceuticals shares are trading higher after the company announced that the FDA lifted the partial clinical hold on studies of azenosertib and remains on track to meet all previously disclosed data guidance for the remainder of 2024.
ZNTL：49% | Zentalis Pharmicals的股價走高，此前該公司宣佈，美國食品藥品管理局取消了對azenosertib研究的部分臨床擱置，並有望在2024年剩餘時間內實現先前披露的所有數據指導。
ITOS: -16% | iTeos Therapeutics shares are trading lower. The company announced follow-up interim data from GALAXIES Lung-201,
ITOS：-16％ | iTEOS Therapeutics的股價走低。該公司公佈了來自 GALAXIES Lung-201 的後續中期數據，